Cardiology Rx (Repurposed)

Testosterone replacement therapy (TRT)

Grade and summary pending review Evidence Grade Strength of published clinical evidence — not a safety rating or a recommendation. How to read this

Dimension Scores

Human Outcome

•

Biomarker Relevance

•

Signal Source Quality

•

Organ Specificity

•

Interaction Certainty

•

Translational Maturity

•

Per-dimension evidence strength is part of the full analysis Unlock full analysis

No indication-level signals recorded yet. The grade above has not been decomposed, so it should be read as a whole-compound assessment rather than a claim about any one indication.

Evidence Summary

For men with DIAGNOSED hypogonadism (clinically low testosterone), a large safety trial (TRAVERSE) found it does not raise major cardiac events, though it carries some real risks. There is NO evidence that testosterone extends healthspan or lifespan in healthy men — its widespread use for 'optimization' or anti-aging is off-label and unsupported.

Safety Considerations

Trial found more atrial fibrillation, other arrhythmias, and acute kidney injury in the testosterone group; caution advised with prior blood-clot events. Evidence applies to diagnosed hypogonadism only. Use in healthy men for 'optimization'/longevity is off-label and not supported by outcome evidence.

Evidence Signals (0)

🔒

Create a free account to see signal-level evidence grades.

Create a free account

Products Containing Testosterone replacement therapy (TRT)

No commercial products are currently listed for this molecule.

This evidence profile reflects publicly available research as of October 22, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.